Data from FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K. Erbe(University of Wisconsin–Madison), Paul M. Sondel(University of Wisconsin–Madison), David F. McDermott(Beth Israel Deaconess Medical Center), Eneida A. Mendonça(Cincinnati Children's Hospital Medical Center), Jacquelyn A. Hank, Mikayla Gallenberger, Sabina Signoretti(Brigham and Women's Hospital), Dustin Hess, Michael B. Atkins(Georgetown University), Jacob L. Goldberg, Lakeesha Carmichael, Wei Wang(Capital Medical University), Su–Chun Cheng, David J. Panka(Hadassah Medical Center), James W. Mier(Hadassah Medical Center), KyungMann Kim(Houston Methodist), Yiqiang Song(Indiana University Bloomington), Alexander Carlson
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k